A research team based out of both University of Iowa and the University of Georgia discovered that their single-dose, intranasal COVID-19 vaccine fully protects mice against lethal COVID-19 infection. Apparently, this early-stage vaccine also blocks animal-to-animal transmission of the virus. With results recently published in the peer-reviewed journal of Science Advances, an operating premise here—and opportunity for commercial partner—is that a new, easier to administer vaccine could help accelerate global vaccination against SARS-CoV-2, the virus behind COVID-19. One of the co-investigators has also set up a startup venture to commercialize the investigational vaccine. Could the upside for an easy to administer, safe, and effective COVID-19 vaccine be worth the wait for the right investor(s)?

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *